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Abstract 
ErbB2, a receptor tyrosine kinase and member of the human EGFR family, is implicated in 30% 
of all breast cancers. Studies have recently shown that the Drosophila EGF receptor (DER) is 
structurally analogous to ErbB2. The transmembrane protein, Kek1, has been shown to bind 
and inhibit DER. By defining sequence elements important for this binding and inhibition, I 
hope to gain insight that may provide an opportunity to generate ErbB2-specific cancer 
therapeutics. 
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Introduction 
There are approximately 11.7million people fighting some type of cancer in the United 
States today. These individuals are fighting malignancies in their brains, kidneys, lungs and 
bloodstreams, just to name a few. Because of this, research into the cause of and potential 
treatments for these cancers are of great interest in our society. There are several different 
factors that may influence an individual’s susceptibility to developing cancer. Some types are 
hereditary and are passed through generations, while others occur spontaneously due to 
mutations in the human genome. Another category of cancers are linked to lifestyle factors, 
such as tobacco use and sun exposure, while other types can be caused by contact with 
chemicals or organisms in the environment (American Cancer Society, 2011). It is needless to 
say when close to 11.7 million people are battling cancer and roughly 200 people out of 
100,000 die every year (National Cancer Institute – Cancer of All Sites, 2010) that these 
diseases must to be studied and therapeutics developed.  
Breast cancer is one of the more common and life-threatening forms of cancer. 
According to the National Cancer Institute, 1 in 8 women will be diagnosed with breast cancer 
in their lifetime (National Cancer Institute – Breast Cancer, 2010). Additionally, it is estimated 
that, in the United States alone, a staggering 207,090 women were diagnosed in 2010 and close 
to 40,000 died due to breast cancer. Treatment options include everything from surgery, to 
radiation and chemotherapy, to targeted therapies that utilize antibodies to block cell signaling. 
One type of breast cancer is caused by the overexpression of the gene for the Epidermal 
Growth Factor Receptor (EGFR) family member, erbB2 (also referred to as HER2). This 
overexpression is responsible for causing roughly 30% of all breast cancers and is implicated in 
other types of cancer as well (Tan, M. and Yu, D.). ErbB2 dependent cancers are more likely to 
result in metastasis and have higher mortality rate. At this point, there are targeted therapies 
that show promise (Tan, M. and Yu, D.). However, a great deal more information needs to be 
obtained in order to fully understand the mechanism behind EGFR related cancers.  
Organisms, such as Drosophila melanogaster, a species of fruit fly, provide model 
experimental systems for such studies. Drosophila have an epidermal growth factor receptor 
(DER) in their proteome that is structurally and functionally similar to ErbB2 (Alvarado et al, 
2009). In flies, DER functions throughout development and is inhibited by Kekkon1 (Kek1) an 
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880 amino acid transmembrane protein. Understanding the functional relationship between 
these two proteins and the mechanism of inhibition, could lead to novel therapeutics for breast 
cancers caused by the overexpression of ErbB2. 
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Background 
Epidermal Growth Factor Receptor Family 
ErbB1 through ErbB4 are members of the EGFR family of receptors  with similar 
structures and functions. Members of this family have been found in a wide variety of species; 
from humans to fruit flies. These receptors have a conserved function as receptor tyrosine 
kinases that are typically activated by extracellular ligand binding. Ligand binding results in the 
phosphorylation of specific tyrosine residues that reside on the intracellular domain of the 
receptor or on other cytoplasmic proteins (Voet, Voet and Pratt, 2008). These receptors are 
involved in the determination of cell lineages and in the development of tissues, such as muscle, 
gastrointestinal, heart and mammary tissues, among many others (Carpenter, 2003; Citri et al, 
2003; Jorissen et al, 2003). Using loss of function and knockout experiments in mice, it was 
determined that the EGFR plays a significant role in the development of epithelial cell tissues, 
shown by severe irregularities of skin, lungs, brain and liver. Additionally, the knockout mice 
also had very short life spans and many died before reaching three weeks of age (Jorissen et al, 
2003). Under normal circumstances, the binding of epidermal growth factors to corresponding 
receptors results in cell proliferation, migration, differentiation and survival (Pimentel, 1994). 
Members of the epidermal growth factor receptor family have a characteristic 
localization and structure. These receptors are often found on the basolateral surface of 
polarized cells, such as epithelial cells (Shelly et al, 2003). Each receptor is comprised of an 
extracellular domain that is responsible for ligand binding, a single transmembrane domain, an 
intracellular region where the highly conserved tyrosine kinase domain is located, and 
cytoplasmic tail for autophosphorylation, as shown in Figure 1.  
 
11 
 
Figure 1: Schematic of EGFR structure 
 
 
The extracellular domain can be divided further into four subdomains, I-IV, or in invertebrates, 
domains I-V. (Ogiso et al, 2002; Schejter et al, 1986; Shilo et al, 1987; Alvarado et al, 2004). 
Subdomains I and III are the location of ligand binding and are lacking in cysteine residues 
(Ogiso et al, 2002). The other two subdomains, II and IV, are rich in cysteine residues and are 
necessary for the formation of dimers and the auto-inhibition of the receptors (Ferguson et al, 
2003). The transmembrane domain of this type of receptor is comprised by a single, alpha-
helical chain that is roughly 20 amino acids long. It is required to anchor the receptor in the cell 
membrane, but it could have additional functions as well (Mendrola, et al, 2002). The last 
region of an EGFR is the intracellular domain. This region is where the kinase domain and the 
crucial tyrosines required for kinase activity are located (Stamos, Sliwkowski and Eigenbrot, 
2002).  
There are several ligands that can bind and activate members of the EGFR family, such 
as transforming growth factor (TGF)-α and neuregulins (Yarden, 2001). In most cases, ligand 
binding triggers the homo- or heterodimerization of these receptors. This dimerization 
propagates the signal through the autophosphorylation of key tyrosine residues located in the 
intracellular region of the receptor (shown in Figure 2). The phosphorylated residues can act as 
docking stations for other proteins that have SH2- or PTB-domains, such as Grb2. A protein 
named Sos interacts with Grb2 to activate Ras, a small G-protein. Ras is anchored in the cellular 
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membrane with a lipid tail (Voet, Voet and Pratt, 2008), and activates Raf, a serine/threonine 
kinase (Prenzel et al, 2001). Activated Raf in turn activates the effector MEK, which is also 
known as MAP kinase kinase. Phosphorylation of MEK activates it, triggering phosphorylation 
of MAP kinase (ERK1/2), to perpetuate the cascade. MAPK then phosphorylates transcription 
factors, such as Fos, Jun or Myc, which control the stimulation of various genes that control cell 
proliferation or cell death, for example.  If this mechanism is incorrectly regulated or the 
receptors are constitutively activated, uncontrolled cell growth can result (Voet, Voet and Pratt, 
2008). 
Figure 2: Map kinase cascade (refer to text for details) 
 
Drosophila melanogaster epidermal growth factor receptor 
As previously mentioned, the EGFR family has members in a wide variety of species. 
Because of this, mechanisms of activation, dimerization and inhibition can be studied in model 
systems. Drosophila has a single EGFR (known as DER) that is structurally and mechanistically 
similar to the human receptors. DER signaling is involved in many processes during 
development, such as oogenesis and embryogenesis, and like the human receptors, can be 
modulated by an assortment of ligands. For example, the EGFR pathway is activated during 
oogenesis and is necessary for the proper organization of the dorsal fates in follicle cells 
(Nilson and Schupbach 1999). 
13 
 
While ligand binding provides one mechanism for regulation of the EGFR family, 
additional mechanisms controlling receptor activation also exist, including regulation of 
receptor stability.  One such additional mode of regulation involves Kek1, which has been 
found to inhibit DER. Kek1 is the founding member of its own family of proteins, known as the 
LIG family. They are characterized by an extracellular domain comprised of a series of leucine-
rich repeats, with cysteine-rich caps on either side, followed by an immunoglobulin domain. 
There are six related LIGs (Kek1-Kek6) in Drosophila, shown in Figure 3, which all have similar 
extracellular domains and relatively divergent intracellular domains (MacLaren et al, 2004). 
Figure 3: The LIG Family in Drosophila 
 
 
Kek proteins have been identified in other arthropod species. These family members have been 
shown to not only have conserved structures and functions, but conserved residues as well 
(Derheimer et al, 2004). In Drosophila, Kek1, but not Keks2-6, has been shown to bind and 
inhibit DER (Alvarado et al, 2004). In vivo, overexpression of Kek1 in D. melanogaster ovaries 
results in a ventralized eggshell phenotype, with a decrease or complete loss of dorsal 
appendages, a phenotype indicative of loss of EGFR activity (Alvarado et al, 2004, Figure 4).  
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Figure 4: Comparison of wild-type chorions and UAS-Kek1 misexpressed chorions 
 
Leucine-Rich Repeats 
Kek1 and its LIG family members have varying numbers of leucine-rich repeats (LRRs) 
in their extracellular regions. LRRs have been found to be present in a striking number of 
molecules, from viruses to eukaryotes and have roles in a range of processes. Each repeat 
stretches about 20-30 amino acids, and as their name suggests, are rich in leucine residues, 
usually in the conserved motif LxxLxLxxNxL (where x is any amino acid) (Kajava, 1998). 
These repeats are usually found in series and the resulting structure, shown in Figure 5, 
is especially suited for protein-protein interactions. This structure is a tightly packed, curved 
coil, where each repeat is a turn of the coil. It is generally thought that the concave side of the 
curved coil is the location of ligand binding (Bella et al, 2008). There is also a parallel β-sheet 
present on the concave side of the coil and a number of other structures on the convex side of 
the coil (Enkhbayar et al, 2004). 
Figure 5: The crystal structure of a leucine-rich repeat domain (PDB ID 2BNH) 
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Oogenesis 
Drosophila oogenesis is a stepwise process that produces eggs in relatively large 
quantities that can be later fertilized. The process starts with the formation of a cystoblast, 
from the division of a germline stem cell. This cystoblast undergoes exactly four rounds of cell 
division, to produce a cyst of 16 cells, termed cystocytes. Follicle cells migrate to cover the 
cystocytes, forming an egg chamber. During this time, one of the 16 cystocytes differentiates 
into an oocyte, which moves within the cyst to set the anterior-posterior orientation of the egg 
chamber, while the others differentiate into nurse cells. The egg chamber continues to mature, 
and is covered with an eggshell. The eggshell has two dorsal appendages that are necessary to 
facilitate respiration. Eggs wait in the ovary for fertilization by a male fly (Deng and Lin, 2001). 
Figure 6: Stages of Drosophila oogenesis (University of Newfoundland, 2010) 
 
DER is expressed in the membrane of the follicle cells that form the egg chamber and is 
required for eggshell patterning (Nilson and Schupbach, 1999; Gonzalez-Reyes and St. 
Johnston, 1998). One of its ligands, Gurken, signals to some cells via DER to adopt a posterior 
fate, as opposed to an anterior fate. Removal of DER signaling in this instance results in the egg 
chamber having a duplicated anterior axis (Gonzalez-Reyes and St. Johnston, 1998). 
Additionally, DER activation is necessary for the proper establishment of the dorsal-ventral 
axis. This selective activation of DER during oogenesis is essential for the proper formation of 
the main body axes (Nilson and Schupbach, 1999). 
Prior research 
Research has been done thus far to characterize the interaction between DER and its 
inhibitor Kek1. It was shown, using a co-immunoprecipitation assay that Kek1 interacts 
directly with DER. This was also shown to be true in vivo, using misexpression of Kek1 during 
oogenesis. This inhibition is characterized by ventralized chorions, indicated by the loss of 
dorsal appendages. Several of the other family members, Kek2, Kek5 and Kek6, do not interact 
with the receptor in vitro (Alvarado et al, 2004). Misexpression experiments with these family 
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members also indicated that the Kek family members do not effectively inhibit DER in vivo, as 
shown by the lack of effects on the dorsal-ventral patterning on the follicle cells (Alvarado et al, 
2004). 
To further characterize the Kek1-DER binding interaction, various swaps involving 
Kek1 and Kek2 were generated and inhibitory activity was studied in vivo. Sections of the 
extracellular and transmembrane domains of Kek1 were fused to Kek2. The first two swaps, 
one consisting of the LRR and Ig regions, the other consisting of just the LRRs, were not able to 
inhibit the receptor in vivo. It was found, however, that the leucine-rich repeats alone are 
sufficient to confer binding, but not inhibition. The last swap, consisting of the entire 
extracellular and transmembrane domains of Kek1 was able to fully inhibit DER in vivo 
(Alvarado et al, 2004). This indicated that the LRRs and the transmembrane region of Kek1 are 
critical for inhibition of the receptor in vivo. 
 Mutation analysis has also been utilized to study this inhibition. Various mutated forms 
of the kek1 transgene were isolated and studied in vivo. These mutations were classified as 
class I or class II alleles of the gene, based on their cellular localization (outlined in Figure 7 
below).  
Figure 7: Schematic of class I and class II alleles (Alvarado et al, 2004) 
 
Alleles belonging to class I are properly localized in the cellular membrane but have reduced 
binding to the receptor and therefore reduced activity in vivo, while alleles belonging to class II 
do not localize to the membrane, and therefore, cannot interact with DER in vivo. The four 
alleles in class I were sequenced and all mutations mapped to the extracellular region of Kek1, 
only in two positions. Specifically, mutations in glycine 160, which is in the second leucine-rich 
repeat, was isolated three times and result in a complete loss in inhibition. This amino acid, 
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glycine 160, is conserved in a variety of Kek1 orthologs, but not present in other Kek family 
members. The class II alleles were found, by co-immunoprecipitation, to completely bind the 
receptor. This indicates that the loss of function of the class II Kek1 alleles is mostly due to their 
abnormal localization observed in vivo (Alvarado et al, 2004). 
The initial discovery of an oncogenic version of the ErbB receptor was shown to map to 
a valine to glutamic acid mutation in the transmembrane domain (Bargmann et al, 1986) 
Consistent with a critical role for the transmembrane domain in ErbB activity, it has been 
shown that the transmembrane domains of ErbB proteins associate during homodimerization. 
This property was shown using the TOXCAT system in Escherichia coli cell membranes, which 
tests the affinity solely of the transmembrane domains, independent of the extracellular and 
intracellular regions (Mendrola et al, 2002). 
A variety of work has supported the notion that transmembrane domains may facilitate 
dimerization by allowing two integral proteins to be in close proximity to each other. This is 
made possible by the presence of specific transmembrane domain motifs that have been found 
to be somewhat characteristic of this type of transmembrane domain. An example of such a 
motif is GxxxG, which creates a cavity in the helix. If another helix has the same type of motif, 
the two can interact more closely, encouraging other areas of the proteins to interact as well. 
The human ErbB receptor tyrosine kinases were found to have two distinct GxxxG motifs, 
which could be essential for the formation of ErbB homo- and heterodimers. It is possible that 
there are other motifs, similar to GxxxG that encourage interaction in other instances, such as 
the interaction between DER and Kek1 (Cymer and Schneider, 2010). 
The goal of this project was to further characterize the interaction between DER and its 
inhibitor, Kek1, based on the structure of Kek1, using both in vivo misexpression and in vitro 
binding assays. The extracellular and intracellular regions of both DER and Kek1 have been 
studied extensively for their role in the mechanism of inhibition. The role of the 
transmembrane domain, however, is not widely understood. There are many transmembrane 
tyrosine kinase proteins that have been studied and found to have very specific, conserved 
motifs in the transmembrane domain. These motifs encourage interaction between proteins by 
allowing the transmembrane alpha-helices to “pack” closely, bringing the extracellular and 
intracellular domains of the proteins close enough to interact (Voet, Voet and Pratt, 2008).  
There is a possibility that the transmembrane regions of DER and Kek1 interact with a similar 
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mechanism.  The potential transmembrane domains of each of these proteins will be defined 
and will be examined for the presence of the known packing motifs, such as the GxxxG motif. 
Aside from these previously described motifs, it is possible that there is some level of 
conservation of transmembrane domains of Kek1 and EGFR across species related to 
Drosophila. These regions will be defined and compared for specific and similar residue 
conservation.  
Materials and Methods 
Mapping of Transgenics 
Males of each transgenic line with eye color were crossed with females of the genotypes 
[w*;Sp/CyO (chromosome II); +/+] and [w*; +/+; Ly/TM3,Sb (chromosome III)]. Heterozygous 
male progeny from these matings were crossed to w1118 females. Using the segregation of the 
eye color and the chromosomal markers, the chromosomal position of the transgene can be 
determined. Segregation with the marker indicates that the transgene is on the same 
chromosome as the marker.  
Once the lines were mapped, balanced stocks were generated by mating 4-5 males of each 
transgenic line to females of the appropriate balancing stock. Males and female progeny of the 
appropriate genotype (P/balancer) were then mated to generate the final balanced stock. 
Misexpression experiments using the GAL4 System 
Drosophila were raised on standard cornmeal media at 25oC – 28oC.  4-5 CY2-GAL4 driver 
females were crossed to males of each transgenic line, to induce misexpression in the follicle 
cells of the female ovaries. Figure 8 shows how the CY2-GAL4 system works in vivo. 
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Figure 8: The CY2-GAL4 system in Drosophila (adapted from Duffy, 2002) 
 
Progeny were placed on an egg lay on apple juice plates for 24-hours. The eggs were washed off 
the plate with dH2O and rinsed many times in dH2O. Eggs were then mounted in 50% lactic acid 
in Hoyers and cured overnight on a 65°C heat block. The chorions were imaged at 10X on Dark 
Field microscopy using the Zeiss Imager.Z. 
 Adult female ovaries were dissected in PBT, fixed in 3.7% formaldehyde with PBT, and 
mounted on a slide in 50% glycerol in PBS. GFP localization and expression of stage 10 ovaries 
were examined using a fluorescent Zeiss Imager.Z microscope with Apotome at 20x or 40x.  
Co-transfections  
An S3 Drosophila cell line was maintained using Schneider’s media with 12.5% FBS. Cells were 
seeded in a 6-well plate at 6x105 cells/well in 2mL of media and transfected when the cells 
were 60-75% confluent using a Qiagen Effectene Transfection Kit. DER-GFP, Kek1 construct-V5 
and mtGAL4 (inducible driver) were co-transfected into each seeded well, for a total of 400ng 
of DNA. Between 22-24 hours later, 1mM CuSO4 was added to each well to induce mtGAL4. The 
cells were harvested at one week. 100ul of cells from each transfection were spun down using a 
tabletop centrifuge for 5 minutes at room temperature. Pellets were resuspended in 50ul 1x 
Sample buffer and 5% BME.  
Western Blots 
Co-transfection samples were run on 8% SDS-PAGE gels according to the (protocol adapted by 
C. Ernst and M. Arata for the Duffy Lab). Protein was transferred onto nitrocellulose 
membranes, which were probed with monoclonal mouse anti-GFP antibody diluted 1:1000 
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with 0.5% NFDM in TBST or monoclonal mouse anti-V5 antibody diluted 1:2000 with 5% 
NFDM in TBST. Goat-anti-mouse secondary antibody was used, diluted 1:20,000 with 5% 
NFDM in TBST. The detection substrate was 1:1 peroxide:luminal solution, and blots were 
developed using an X-omat and Kodak film.  
Co-immunoprecipitation Assay 
Cells co-transfected with DER-GFP, Kek1 construct-V5 and mtGAL4 (inducible driver) and 
induced as described above were pelleted at 2000rpm for 2 minutes at 4°C. Cells were then 
lysed in ice cold Fehon buffer with detergents (1%NP-40 and 0.5% sodium deoxycholate) and 
protease inhibitors. After 15 minutes, the cells were spun down at max speed for 5 minutes at 
4°C. The supernatant was immunoprecipitated using rabbit anti-GFP polyclonal antibody 
(Clonetech), and rotated overnight at 4°C. 50ul Protein A Sepharose beads per reaction were 
washed in Fehon buffer and detergents, then added to each sample, and incubated for 1.5 hours 
at 4°C. The beads were then washed in Fehon buffer and detergents, then in Fehon buffer. 
Samples were prepared for Western blots in 2X Sample buffer, 5% BME and TBS and boiled for 
4 minutes at RT.  
Identifying potential transmembrane domain sequences 
Various transmembrane domain prediction programs were chosen to be used in this analysis 
(DAS, SOSUI, TMHMM, Tmpred, SPLIT 4.0, Phobius, Rhythm). Amino acid sequences for DER 
and Kek1 were obtained via NCBI and plugged into these internet-based programs. The results 
from each analysis were considered and the most commonly predicted start and end residues 
in the approximate location of the transmembrane domain were selected. 
Results 
To gain a better understanding of the sequence requirements for Kek1 binding to the 
EGFR, three different types of Kek1 chimeras (Figure 9) were previously generated and used to 
produce transgenic D. melanogaster flies. In all cases, the chimeras had a C-terminal GFP fusion 
tag to allow for localization in vivo, and precipitation studies in vitro. Two of the chimeras had 
Kek1 backbones, one with the second leucine-rich repeat replaced by the one from Kek2 
(K1K2L2) and the other with the fourth through the seventh leucine-rich repeats replaced by 
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those of Kek2 (K1K2L4-7). The last chimera had the first through the third leucine-rich repeats of 
Kek1 on the Kek2 backbone (K2K1L1-3).  
Figure 9: Schematic of the Kek1/Kek2 chimeras 
 
These chimeras were designed based on the fact that several non-functional Kek1 mutants had 
point mutations in the first through the third LRRs, and that the second LRR (where glycine 
160 resides) is especially important for binding and inhibition. Based on this information, 
removing the second LRR of Kek1 and replacing it with the second LRR of Kek2 should reduce 
or eliminate inhibition of the receptor. Similarly, adding the first through the third leucine-rich 
repeats of Kek1 onto a Kek2 backbone should confer binding. The last swap, replacing the 
fourth through the seventh leucine-rich repeats of Kek1 with those of Kek2, should retain 
binding and inhibition, as this region is not believed to be as crucial as LRRs 1-3 and specifically 
LRR 2. 
The interaction between these chimeric proteins and DER was studied in vivo and in 
vitro, using the CY2-GAL4 system and a co-immunoprecipitation assay. In vivo, it was necessary 
to look for proper localization, as well as the potential inhibition of DER. If changing the 
leucine-rich repeats changes protein structure, the protein will not fold correctly and, thus, 
may not end up co-localized with DER in the cell membrane. The co-immunoprecipitation assay 
was used to test for direct binding of the chimeras.  
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Mapping of Chimera Transgenics 
Transgenic flies with K1K2L4-7, K1K2L2 or K2K1L1-3 inserts were mated as described in the 
Materials and Methods to determine the chromosome insertion for each transgene line. Five 
K2K1L1-3 and nine K1K2L2 lines were mapped using this method. The results are shown in Table 1.  
Table 1: Results of mapping transgenic flies 
JHK1K2L2 
Line Chromosome  Eye Color 
1M III red orange 
4M In progress - 
5M II light orange 
14M III light orange 
15M II bright red 
7F II light orange 
8F II light orange 
11F In progress - 
18F In progress - 
   
JHK1K2L4-7 
Line Chromosome Eye Color 
1M II orange and bright red 
9M III orange and bright red 
18M II orange and red orange 
23M III bright red 
   
JHK2K1L1-3 
Line Chromosome Eye Color 
9M III orange 
11M IV - 
12M III light orange 
19M III yellow orange 
22F III orange 
 
In vivo functional studies 
 The in vivo analysis was done two different ways. Transgenic males were crossed to 
CY2-GAL4 virgins and ovaries from female progeny were dissected, fixed, and mounted to be 
examined using fluorescence microscopy. This was performed to show the localization of the 
GFP-tagged Kek chimeric variants in the follicle cells of S9-10 egg chambers (Figures 10 – 13). 
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Wild-type Kek1 localizes to the apical and lateral membranes, as shown by the GFP localization 
in Figure 10.  
Figure 10: UAS-Kek1 misexpression in late stage 9 egg chamber; surface view (left), lateral view 
(right) 
  
The chimeric variant K1K2L2 localizes similarly as most of the GFP expression is also localized to 
the apical and lateral membranes of the follicle cells, shown below.  
Figure 11: K1K2L2 misexpression in stage 10 egg chambers; surface view (left), lateral view (right) 
   
In contrast, the next variant, K1K2L4-7 displays significantly different GFP, and thus variant 
localization. The GFP is excluded from the cellular membrane of the follicle cells, and is 
exclusively in the cytoplasm.  
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Figure 12: K1K2L4-7 misexpression in stage 10 ovaries; surface view (left), enlarged lateral view (right) 
   
The last variant, K2K1L1-3 has a different backbone than the other two (Kek2). Kek2 has a 
different localization pattern than Kek1. It localizes to the apical and basal membranes of the 
follicle cells, as opposed to just the apical membrane. This last variant localizes like Kek2, as 
shown in Figure 13 below.  
Figure 13: K2K1L1-3 misexpression in stage 10 egg chambers; surface view (left), lateral view (right) 
                
Based on these images, it would be expected that K1K2L4-7 would not be able to bind DER in vivo, 
since it is localized to the cytoplasm as opposed to the cellular membrane. The other two 
variants, K1K2L2 and K2K1L1-3 have the potential to bind DER, since they are co-localized with the 
receptor.  
To address functionality in vivo, each chimera was assessed for the ability to inhibit DER 
signaling during oogenesis.  The female progeny from the same transgene - CY2/GAL4 crosses 
were placed on apple juice egg lay plates. After 24 hours, the chorions were collected, mounted 
and examined for the presence or absence of dorsal appendages. The absence or reduction of 
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appendages (ventralization) indicates inhibition of DER by Kek1, as shown by the chorions 
derived from females misexpressing Kek1 in the follicle cells (CY2>Kek1) in Figure 14.  
Figure 14: UAS-Kek1 misexpression in chorions; complete loss of appendages (left), reduction in 
appendages (right) 
 
 
The chorions of the three Kek1 chimeras are shown in Figure 15, and do not show any 
reduction of the appendages.  
Figure 15: Misexpression of chimeric variants in chorions; K1K2L2 (left), K1K2L4-7 (middle), K2K1L1-3 
(right) 
           
This indicates that the chimeras were not able to inhibit the receptor in vivo, despite the proper 
localization of two of the variants.  
In vitro functional studies 
The in vitro studies were based on the co-immunoprecipitation assay, where tagged 
versions of DER and the chimeric variants were expressed in Drosophila S3 cells. Expression 
was through the CY2-GAL4 system, outlined in Figure 16.  
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Figure 16: The CY2-GAL4 system for expressing proteins in cell culture 
 
These cells were lysed, and through the use of Protein A sepharose beads and antibodies 
specific for the receptor tags, the interaction (if any) of the receptor and the Kek1 variants can 
be assessed, as shown in Figure 17.  
Figure 17: Schematic of the Co-immunoprecipitation assay 
 
Results for this particular assay proved to be elusive, requiring a series of trouble-
shooting experiments be performed. The most predominant issue with the running of the co-ip 
assays was the lack of bands on the developed control western blot. This blot was probed for 
the presence or absence of the V5 tagged Kek1 chimeras and the GFP tagged DER proteins in 
whole cell lysate and no bands were detected on the film.  
There are many possible explanations for this kind of result. It was possible that the gel 
was being overloaded with too much protein or underloaded with not enough protein from the 
whole cell lysate. Another possibility was that there could be incomplete or lack of transfer 
from the protein gel to the nitrocellulose membrane, or a problem with detection following the 
transfer. It is also possible that not enough probing antibody was being used or the transfection 
efficiency was too low to produce detectable amounts of either protein.  
After establishing the different points where problems could arise, different 
experiments were conducted to find the source of the problem. The first was to test to see if the 
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gel was being overloaded or underloaded. Different amounts of cells (from 25ul to 100ul) from 
distinct transfections were harvested and run on an SDS-PAGE protein gel and then Coomassie 
stained. A photo of the stained gel is shown in Figure 18.  
Figure 18: Coomassie stained SDS-PAGE gels 
 
The presence of bands indicates that proteins from the lysates are being separated on the gel 
and thus it is not being overloaded. 
From here, it was necessary to check if the protein was not being transferred properly 
from the gel to the nitrocellulose membrane. This was assayed in conjunction with the levels of 
primary antibody. Set-up of a gel for GFP tagged samples is shown in Figure 19. The similar gel 
for V5 tagged samples was set up the same way, with secreted Kek1-V5 as a control and anti-V5 
antibody concentrations of 1:5000, 1:2000, and 1:1000. 
Figure 19: Schematic of experiment to test primary antibody concentrations 
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The nitrocellulose strips were probed with the same secondary antibody and developed as 
usual. The anti-GFP probed membrane produced bands corresponding to DER-GFP in the 
whole cell lysate lanes and secreted Kek1-GFP in the control lanes after a 10 minute exposure. 
This blot is shown in Figure 20.  
Figure 20: Anti-GFP probed western blot 
 
Interestingly, the membrane probed with anti-V5 produced no bands after a 10 minute 
exposure. Following the running of the transfer, the gels were Coomassie stained, to see if there 
was incomplete transfer of the protein to the nitrocellulose. There were very faint streaks on 
the Coomassie stained gel, indicating that the transfer was essentially complete.  
 Due to the presence of bands on the GFP-probed blot and the absence of bands on the 
V5 probed blot, it was thought that the V5 antibody could be faulty. To test this, another 
protein gel was run with secreted Kek1-V5 and whole cell lysate, transferred to a membrane 
and probed with the same V5 antibody as before, a V5 antibody borrowed from another lab and 
a tubulin antibody, as shown in the schematic below (Figure 21).  
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Figure 21: Schematic of experiment to test different V5 antibodies 
 
Faint bands appeared following a 20 minute exposure, associated with Kek1 construct tagged 
with V5 and tubulin. No bands corresponded to the control Kek1-V5. 
Transmembrane domain analysis 
To further define sequences in Kek1 important to inhibition of DER, work was 
undertaken to better characterize the sequences in the transmembrane domain of Kek1. In 
order to study the function of the transmembrane domain, it is important to first identify 
residues involved. A total of seven internet-based prediction programs were utilized in this 
process, and the results from each were considered, as shown in Table 2. The most commonly 
predicted sequence of residues was selected as the transmembrane domain for these studies.  
Table 2: Results of the Kek1 and DER transmembrane analysis 
  
Kek1 DER 
Start End Length Start End Length 
DAS 445 467 23 866 888 23 
SOSUI 445 467 23 870 892 23 
TMHMM 445 467 23 867 885 19 
Tmpred 449 467 19 866 892 27 
SPLIT 4.0 443 468 26 869 892 24 
Phobius 444 467 24 869 892 24 
Rhythm 444 467 24 868 890 23 
Predicted Tm 444 467 24 868 892 25 
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 The amino acid sequences for Kek1 and DER were blasted using the NCBI database, to 
determine whether the transmembrane domains of these proteins are conserved in other 
species. Sequences were obtained for Anopheles gambiae (mosquito), Apis mellifera (honey 
bee), Tribolium castaneum (beetle) and Daphnia pulex (crustacean), and the transmembrane 
domains were aligned, as shown in Figure 22.  
Figure 22: Transmembrane domain alignments; Kek1 orthologs (top), EGFR orthologs (bottom) 
 
Conserved residues are highlighted in the alignment. The transmembrane regions are 
highlighted in gray, while blue corresponds to conservation of similar residues and pink 
corresponds to conservation of identical residues.   
Using the hypothetical sequences of amino acids that correspond to the alpha helices of 
the Kek1 and DER transmembrane domains, helical-wheel diagrams were created, based on the 
one drawn by Cymer and Schneider (2010). The diagrams for Kek1 and DER are shown in 
Figure 23. Residues with red text are conserved throughout all the species analyzed, while 
yellow text indicates residues conserved from Drosophila through Tribolium.   
Figure 23: Kek1 Helical-Wheel Diagram (left) and EGFR Helical-Wheel Diagram (right) 
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Notice the moderate level of conserved identical residues in the transmembrane region and 
adjacent extracellular and intracellular regions throughout all five species of Kek1, and the lack 
of any type of conservation in the EGFR transmembrane domains (Figure 22). 
Discussion 
In vivo Functional Studies 
 The first round of in vivo studies showed that the chimeras did not effectively inhibit 
DER, shown by the chorions retaining their appendages. There are two possibilities that would 
produce this outcome. The first is that the chimeras are not capable of inhibiting the receptor in 
vivo. Changing the leucine-rich repeats as described previously was enough to eliminate or 
severely reduce the amount of interaction between DER and Kek1. It is equally as possible that 
modifying the chemistry of Kek1 or Kek2 by swapping the leucine-rich repeats produces an 
unfolded protein or a protein that does not localize to the cellular membrane. If this is the case, 
the chimeras cannot directly interact with the receptor because they are not in the right 
proximity to do so.  
The examination of GFP expression in the stage 10 egg chambers can indicate whether 
the chimeras are properly localized or not. Kek1, when misexpressed, localizes to the apical 
membrane of the follicle cells. The chimeric variants with the Kek1 backbone were expected to 
localize similarly, if a functional protein was produced. K1K2L2 mostly localizes to the apical 
membrane, as it should. However, there may be some degree of mislocalization, shown by the 
punctate nature of the GFP expression, indicating that there may be some trafficking 
deficiencies involved with changing the LRR structures. The other variant with a Kek1 
backbone, K1K2L4-7, did not localize as expected, but was exclusively in the cytoplasm and 
excluded from the apical membrane.  The last variant, K2K1L1-3, has a different backbone than 
the others. Kek2 has a different localization pattern than Kek1. It is expressed in the membrane 
of the follicle cells, as well, but it is limited to the apical membrane. The variant localizes in a 
similar pattern to wild-type Kek2, but with trafficking deficiencies similar to what was seen 
with the K1K2L2 variant.  
Examination of the chorions and the presence or absence of dorsal appendages is 
necessary to observe whether the chimeric variants were able to inhibit DER. Because K1K2L4-7 
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does not localize to the membrane, it cannot inhibit the receptor, which is shown by the 
respective chorions. The other two variants do localize to the proper membrane, and have the 
potential to inhibit. Based on what is known about the chemistry of this interaction, LRR2 of 
Kek1 is crucial for binding of the receptor. K1K2L2 does not have the correct LRR but does have 
the transmembrane domain of Kek1, which is necessary for inhibition. Because of this, it would 
be expected that this chimeric variant would not be able to inhibit the receptor in vivo. The 
chorions for this variant do not show any reduction in dorsal appendages, indicating that 
inhibition is lost with the exchange of LRR2. The last variant, K2K1L1-3 has the transmembrane 
domain of Kek2, and lacks the transmembrane domain of Kek1 which is essential for inhibition 
in vivo, so it would be expected that this variant would not inhibit the receptor, but might be 
able to bind in vitro. This is confirmed by the phenotype observed in the chorions, with no 
reduction or loss of dorsal appendages.  
In vitro Functional Studies 
The co-IP and control western blot did not produce any results demonstrating binding or lack 
of binding for the chimeric variants to DER. The assay required some troubleshooting, due to a 
transition to an Effectene transfection protocol from electroporation.  
 Based on the results of the troubleshooting, it seems that there are a few places where 
optimization is necessary. The Coomassie stained gel affirms that the gel is not being 
overloaded or underloaded. Based on the bands on the GFP and V5 probed blots, the antibodies 
are fully functional, and the standard levels of antibody seem to be sufficient. Optimization of 
the transfection is essential. The faint bands on the blots indicate low expression. Really low 
levels of expressed protein result in a reduced chance of a successful immunoprecipitation, 
especially if the proteins of interest bind with low affinity. Contributing to the unreliability of 
the western blots could be human error in any of the steps of the protocol. 
Initial characterization of the transmembrane domains of DER and Kek1 
The identification of the transmembrane domains of these proteins is a first step in 
characterizing the role of these regions in binding and inhibition. While the prediction 
programs do not produce a definitive answer, they give a pretty good indication of where to 
expect the transmembrane domain and where to direct in vivo and in vitro analysis of the 
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region.  The generation of the helical-wheel diagrams are helpful for visualizing the different 
faces of the alpha helix that could be involved in interactions with other proteins.  
Studies involving the transmembrane domains of the human ErbB receptors have 
shown conserved GxxxG or SxxxG motifs are crucial for the proper dimerization of the 
receptors. It was thought that since the ErbBs and DER have similar structures and functions, 
that there is a possibility of the presence of one of these motifs in the transmembrane domain 
of DER. Examination of the predicted amino acid sequence and the helical-wheel diagram for 
DER does not prove this to be true. These known motifs do not appear in the transmembrane 
domain of DER. This does not suggest that this region does not play a role in the interaction 
between DER and Kek1. It only shows that, if it does play a role, it does not do so through the 
previously studied motifs.  
 It was originally thought that if there was some level of conservation in the 
transmembrane domains of the Kek1 orthologs that the EGFR orthologs would follow with 
some conservation of residues. This would suggest a simple model with a potentially sequence-
based interaction between the two domains that allows for the proper inhibition of the 
receptor in vivo.  The alignments show, however, that while there is some level of conservation 
of the Kek1 transmembrane domains, the EGFR transmembrane domains do not seem to follow 
this trend. There is a striking dissimilarity across all of the species analyzed. This indicates that 
the interaction between the transmembrane domains during inhibition is more complicated 
than originally anticipated and that the simple model does not fit the data shown.  
  While this data suggests that the role of the transmembrane domain during inhibition 
is more complicated than previously thought, there are a few possible reasons for the lack of 
conservation among the EGFR orthologs and conservation among the Kek1 orthologs.  There is 
a possibility that the Kek1 orthologs in organisms other than Drosophila do not inhibit their 
respective EGFRs in vivo, and that this inhibition is limited to Drosophila. If this is the case, 
there would be no need for there to be conservation across species. This may not be the case 
because there is conservation in one and not the other. On another note, Moriki et al propose 
an activation mechanism of EGFR involving dimerization and rotation of the juxta-
transmembrane and the transmembrane domain of the receptor. It is possible that the Kek1 
transmembrane domain sterically blocks this rotation, eliminating the possibility of activation. 
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